NOTICE OF 39TH ANNUAL GENERAL MEETING

Notice is hereby given that the 39th Annual General Meeting ('AGM') of the members of Dr. Reddy's Laboratories Limited will be held on Thursday, July 27, 2023, at 10:00 a.m. (IST) through Video Conferencing ('VC')/ Other Audio-Visual Means ('OAVM'), to transact the following business:

ORDINARY BUSINESS

1. To receive, consider and adopt the Audited Financial Statements (Standalone and Consolidated) of the Company for the financial year ended March 31, 2023, together with the Reports of the Board of Directors and Auditors thereon.
2. To declare dividend of ₹40 per equity share for the financial year ended March 31, 2023.
3. To re-appoint Mr. G V Prasad (DIN: 00057433), as a Director, who retires by rotation, and being eligible offers himself for re-appointment.

SPECIAL BUSINESS

4. **Appointment of Dr. Claudio Albrecht (DIN: 10109819), as an Independent Director of the Company, in terms of Section 149 of the Companies Act, 2013**

   To consider and, if thought fit, to pass, the following resolution as a special resolution:

   "RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, 161 read with Schedule IV and other applicable provisions of the Companies Act, 2013, together with the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force), and Regulations 17(1C), 25(2A) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and Articles of Association of the Company, and approval and recommendation of the Nomination, Governance and Compensation Committee and that of the Board of Directors, Dr. Claudio Albrecht (DIN: 10109819), appointed as an Additional Director of the Company, categorised as independent, with effect from May 10, 2023, in terms of Section 161 of the Companies Act, 2013 and in respect of whom the Company has received notice in writing under Section 160 of the Companies Act, 2013, from a member proposing him as a Director, be and is hereby appointed as an Independent Director of the Company, for a term of five consecutive years effective from May 10, 2023 till May 9, 2028, not be liable to retire by rotation;

   RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorised to do and perform all such acts, deeds, matters and things, as may be considered necessary, desirable or expedient to give effect to this resolution."

5. **Re-appointment of Mr. Leo Puri (DIN: 01764813) as an Independent Director for a second term of five years, in terms of Section 149 of the Companies Act, 2013**

   To consider and, if thought fit, to pass, the following resolution as a special resolution:

   "RESOLVED THAT pursuant to the provisions of Sections 149 and 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013, together with the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force) and Regulations 17(1C), 25(2A) and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and Articles of Association of the Company, and approval and recommendation of the Nomination, Governance and Compensation Committee and that of the Board of Directors, Mr. Leo Puri (DIN: 01764813) who had been appointed as an Independent Director of the Company for a period of five years with effect from October 25, 2018, up to October 24, 2023, by the shareholders at the 35th Annual General Meeting ('AGM'), in terms of Section 149 of the Companies Act, 2013, be and is hereby re-appointed as an Independent Director of the Company for a second term of five consecutive years, with effect from October 25, 2023, till October 24, 2028, not liable to retire by rotation;

   RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorised to do and perform all such acts, deeds, matters and things, as may be considered necessary, desirable or expedient to give effect to this resolution."

6. **Re-appointment of Ms. Shikha Sharma (DIN: 00043265) as an Independent Director for a second term of five years, in terms of Section 149 of the Companies Act, 2013**

   To consider and, if thought fit, to pass, the following resolution as a special resolution:

   "RESOLVED THAT pursuant to the provisions of Sections 149 and 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013, together with the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force) and Regulations 17(1C), 25(2A) and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and Articles of Association of the Company, and approval and recommendation of the Nomination, Governance and Compensation Committee and that of the Board of Directors, Ms. Shikha Sharma (DIN: 00043265) who had been appointed as an Independent

Director of the Company for a period of five years with effect from January 31, 2019, up to January 30, 2024, by the shareholders at the 35th Annual General Meeting ('AGM'), in terms of Section 149 of the Companies Act, 2013, be and is hereby re-appointed as an Independent Director of the Company, for a second term of five consecutive years, with effect from January 31, 2024, till January 30, 2029, not liable to retire by rotation;

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorised to do and perform all such acts, deeds, matters and things, as may be considered necessary, desirable or expedient to give effect to this resolution."

7. **Remuneration payable to Cost Auditors, M/s. Sagar & Associates, Cost Accountants, for the financial year ending March 31, 2024**

To consider and, if thought fit, to pass, the following resolution as an ordinary resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 148(3) and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modifications and re-enactment thereof, for the time being in force), the remuneration payable to M/s. Sagar & Associates, Cost Accountants (Firm Registration No. 000118), appointed by the Board of Directors, on the recommendation of the Audit Committee, as Cost Auditors of the Company to conduct audit of cost records of the Company, for the financial year ending March 31, 2024, amounting to ₹9,00,000/- (Rupees Nine Lakhs only) plus applicable taxes and out of pocket expenses at actuals, in connection with the aforesaid audit, be and is hereby ratified;

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all such acts, matters, deeds and things, as may be necessary to give effect to this resolution."

By order of the Board of Directors
For **Dr. Reddy's Laboratories Limited**

Sd/-
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Membership No.F6621

Place: Hyderabad
Date: May 10, 2023

Registered Office
8-2-337, Road No. 3, Banjara Hills,
Hyderabad, Telangana- 500034, India
CIN: L85195TG1984PLC004507
Tel: 91-40-49002900, Fax: 91-40-49002999
Email: shares@drreddys.com
Website: www.drreddys.com

NOTES

1) The explanatory statement pursuant to Section 102 of the Companies Act, 2013 ('Act') and the Rules made thereunder, Secretarial Standard on General Meetings (SS-2) and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') wherever applicable, in respect of the special business set out in the Notice, is annexed hereto. The Board of Directors of the Company at its meeting held on May 10, 2023, has considered and recommended to include item nos. 4, 5, 6 and 7 of the special business in the Notice for approval of the members at the 39th Annual General Meeting ("AGM") of the Company.

2) Pursuant to General Circular Nos. 14/2020, 17/2020, 20/2020, 02/2021, 2/2022 and 10/2022 dated April 8, 2020, April 13, 2020, May 5, 2020, January 13, 2021, May 5, 2022 and December 28, 2022, respectively, issued by the Ministry of Corporate Affairs ('MCA') and Securities and Exchange Board of India ('SEBI') Circular Nos. SEBI/HO/CFD/CMD1/CIR/P/2020/79, SEBI/HO/CFD/CMD2/CIR/P/2022/62 and SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated May 12, 2020, May 13, 2022 and January 5, 2023, respectively (collectively referred to as 'Circulars'), companies are permitted to hold the AGM through VC/ OAVM, without the physical presence of the members at a common venue. Accordingly, the 39th AGM of the Company will be held through VC/ OAVM in compliance with the provisions of the Act and Rules made thereunder, the SEBI Listing Regulations read with the aforesaid Circulars. The deemed venue for the 39th AGM shall be the Registered Office of the Company, i.e. 8-2-337, Road No. 3, Banjara Hills, Hyderabad – 500034, Telangana, India.

3) In line with the Circulars, the Company is providing VC/ OAVM facility to its members to attend the 39th AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited ("NSDL"), as the authorised agency for facilitating voting through electronic means. The facility of casting votes by a Member using remote e-voting system as well as e-voting on the date of the AGM will be provided by NSDL.

4) The facility for attending the AGM virtually will be made available for 1,000 members on first come first served basis. This will not include large members (i.e. members with 2% or more shareholding), Promoters, institutional investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination, Governance and Compensation Committee and Stakeholders' Relationship Committee, Auditors, etc. who are allowed to attend the AGM without restriction on first come first served basis.

5) The VC/ OAVM facility for members to join the meeting, shall be kept open 30 minutes before the start of the 39th AGM and will be closed on expiry of 30 minutes after closure of the 39th AGM. Members can attend the 39th AGM through VC/ OAVM by following the instructions mentioned in this Notice.

6) Corporate members whose authorised representatives are intending to attend the meeting are requested to send a certified copy of the Board resolution authorising such representative to attend the 39th AGM through VC/ OAVM, and cast their votes through e-voting. Such documents can be sent to drlscrutinizer@gmail.com, with a copy marked to evoting@nsdl.co.in.

7) Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG format) of the relevant Board Resolution/ Authority letter etc. who are authorised to vote, to the Scrutiniser by e-mail at drlscrutinizer@gmail.com with a copy marked to evoting@nsdl.co.in.

8) Members attending the 39th AGM through VC/ OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.

9) The statutory registers including Register of Directors and Key Managerial Personnel and their shareholding, the Register of Contracts or Arrangements in which Directors are interested, maintained under the Act and the Certificate from the Secretarial Auditors of the Company certifying that the ESOP Schemes of the Company are being implemented in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, will be available for inspection by the members during the 39th AGM. All documents referred to in the Notice and Explanatory Statement will be available for inspection in electronic mode from the date of circulation of this Notice up to the date of the 39th AGM. Members who wish to inspect the register are requested to write to the Company by sending e-mail to shares@drreddys.com.

10) In accordance with the aforesaid Circulars, the Notice of the 39th AGM along with the Integrated Annual Report for the financial year ended March 31, 2023, has been sent only through electronic mode to the members who have registered their e-mail addresses with the Company/ Depository Participants. The Notice of 39th AGM and Integrated Annual Report are also available on the Company's website at *www.drreddys.com,* on the website of the Stock Exchanges, i.e. BSE Limited ('BSE') at *www.bseindia.com* and National Stock Exchange of India Limited ('NSE') at *www.nseindia.com* and on the website of National Securities Depository Limited ('NSDL') at *https://www.evoting.nsdl.com/*

11) In accordance with the aforesaid Circulars, no physical copy of the Notice of the 39th AGM and the Integrated Annual Report for the year ended March 31, 2023, has been sent to members. Digital copy of the Integrated Annual Report has been sent to those members whose e-mail addresses are registered with the Company/ Depository Participants.

12) In accordance with the Circulars, members who have not registered their e-mail address may register their e-mail address on *www.drreddys.com/investors/investor-services/shareholder-information* or with their Depository Participant or send their request at shares@drreddys.com along with their Folio No./ DP ID and Client ID and valid e-mail address for registration.

13) Pursuant to Section 108 of the Act, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Regulation 44 of the SEBI Listing Regulations and the aforesaid Circulars, the Company is pleased to offer voting by electronic means to the members to cast their votes electronically on all resolutions set forth in this Notice. The detailed instructions for e-voting and attending the 39th AGM through VC/ OAVM are given as a separate attachment to this Notice.

14) Members are requested to intimate immediately, any change in their address to their Depository Participants with whom they are maintaining their demat accounts. If the shares are held in physical form, change in address has to be intimated to the Company's Registrar and Transfer Agent (RTA), Bigshare Services Private Limited, 306, Right Wing, 3rd Floor, Amrutha Ville, Opp. Yashoda Hospital, Rajbhavan Road, Hyderabad 500 082, Telangana, India Tel: +91-40-2337 4967, Fax: +91-40-2337 0295, e-mail ID: bsshyd@bigshareonline.com.

15) The Register of Members and Share Transfer Books of the Company will remain closed from Wednesday, July 12, 2023, to Friday, July 14, 2023 (both days inclusive).

16) The Board of Directors of the Company at their meeting held on May 10, 2023, has recommended a dividend of ₹40/- per equity share of face value of ₹5/- each as final dividend for the financial year ended March 31, 2023. Dividend, if declared, at the 39th AGM, will be paid on August 1, 2023, subject to deduction of tax at source to those members whose names appear on the Register of Members of the Company as of end of the day on July 11, 2023.

17) In terms of Schedule I of the SEBI Listing Regulations, listed companies are required to use the Reserve Bank of India's

approved electronic mode of payment such as electronic clearance service (ECS), LECS (Local ECS)/RECS (Regional ECS)/NECS (National ECS), direct credit, real time gross settlement, national electronic fund transfer (NEFT), etc. for making payments like dividend etc. to the members.

Accordingly, members holding securities in demat mode are requested to update their bank details with their Depository Participants. Members holding securities in physical form are required to send a request updating their bank details, to the Company's RTA.

18) The Company shall dispatch by post the dividend warrants to those members who have not registered their bank mandate with the Company. Pursuant to the Income Tax Act, 1961 ('the IT Act'), as amended by the Finance Act 2020, dividend income will be taxable in the hands of the members and the Company is required to deduct tax at source (TDS) from dividend paid to members at the prescribed rates, as detailed hereunder:

For Resident shareholders, taxes shall be deducted at source under Section 194 of the IT Act, as follows:

Valid PAN of shareholder available with the Company	10% or as notified by the Government of India
Shareholders without PAN/ invalid PAN with the Company	20% or as notified by the Government of India
Shareholder covered under Section 206AB of the IT Act as per utility prescribed by CBDT	20%

However, no tax shall be deducted on the dividend payable to a resident individual shareholder if the total dividend to be received by them during the financial year 2023-24 does not exceed ₹5,000/- and also in cases where shareholder provide valid Form 15G (applicable to any person other than HUF or a Company or a firm)/ Form 15H (applicable to an individual who is 60 years and older) subject to conditions specified in the IT Act. Shareholders may also submit any other document as prescribed under the IT Act to claim a lower/ nil withholding tax. PAN is mandatory for shareholders providing valid Form 15G/ Form 15H or any other documents as mentioned above. The formats of Form 15G/ Form 15H are also available on the website of the RTA, Bigshare Services Private Limited at *https://www.bigshareonline.com/*

For Resident Mutual funds and Insurance Company shareholders

In order to provide exemption from TDS on the dividend payable to a Mutual Fund specified under clause (23D) of Section 10 of the IT Act or an Insurance Company as specified in Section 194 of the IT Act, shareholders should submit the below document along with exemption notification, if any, as per the relevant provisions of the IT Act:

a. Declaration by shareholder qualifying as Insurer as per Section 2(7A) of the Insurance Act, 1938.

b. Declaration by Mutual Fund shareholder eligible for exemption under Section 10(23D) of the IT Act.

c. Declaration by Category I/ II Alternate Investment Fund (AIF) registered with SEBI.

Declaration for exemption under Circular 18/2017 of the IT Act

In case of any shareholder whose income is subject to lower rate of TDS or is exempt under the IT Act, such shareholder is requested to submit the following documents, if eligible as per the relevant provisions of the IT Act, duly signed by the authorised signatory:

a. Lower withholding tax certificate for the financial year 2023-24, if any obtained from the Income Tax authorities.

b. In case the shareholder has obtained tax exemption status under any provisions of the IT Act, the documentary evidence along with declaration for the same.

For Non-Resident shareholders, taxes are required to be withheld in accordance with the provisions of Section 195 and other applicable sections of the IT Act, at the rates in force. The withholding tax shall be at the rate of 20% (plus applicable surcharge and cess) or as notified by Government of India on the amount of dividend payable. However, as per Section 90 of the IT Act, non-resident shareholders may have an option to be governed by the provisions of the Double Tax Avoidance Treaty (DTAA) between India and the country of tax residence of the shareholder, if they are more beneficial to them. In order to avail the benefits of DTAA, the non-resident shareholders will have to provide the following:

- Self-attested Tax Residency Certificate (TRC) for the financial year 2023-24, obtained from the tax authorities of the country of which the shareholder is a resident.
- Self-attested copy of PAN allotted by the Indian Income Tax authorities. In case of non-availability of PAN, information under Sub-rule 2 of Rule 37BC of the Income Tax Rules to be submitted.
- Form 10F as per the format specified under the IT Act.

Pursuant to Notification no. 03/2022 dated July 16, 2022, non-resident members are required to furnish Form 10F electronically on income tax portal with their login credentials at eportal.incometax.gov.in.

Non-resident members who are not having Permanent Account Number ('PAN') in India or who are not required to obtain PAN in India are exempted from mandatory electronic filing of Form 10F, however, they are required to submit the manual Form 10F duly signed along with a declaration of not having PAN or not required to obtain PAN in India.

- Self-declaration from non-resident shareholder addressed specifically to the Company, primarily covering the following:

    a. Non-resident is and will continue to remain a tax resident of the country of residence during the financial year 2023-24;

    b. Non-resident is eligible to claim the benefit of respective tax treaty;

    c. Non-resident has no reason to believe that its claim for the benefits of the DTAA is impaired in any manner;

    d. Non-resident receiving the dividend income is the beneficial owner of such income;

    e. Dividend income is not attributable/effectively connected to any permanent establishment (PE) or fixed base in India;

    f. In case of Foreign Institutional Investors and Foreign Portfolio Investors, self-attested copy of SEBI registration certificate; and

    g. In case of shareholder being tax resident of Singapore, furnish the letter issued by the competent authority or any other evidences demonstrating the non-applicability of Article 24 - Limitation of Relief under India-Singapore Double Taxation Avoidance Agreement (DTAA).

- Any other documents as prescribed under the IT Act for lower withholding tax if applicable, duly attested by the shareholder.

The Company is not obligated to apply the beneficial DTAA rates at the time of tax deduction/ withholding on dividend amounts. Application of beneficial DTAA rate shall depend upon the completeness and satisfactory review by the Company, of the documents submitted by non-resident shareholder.

Declaration by shareholders under Rule 37BA (2) of the Income Tax Rules, 1962

In order to enable the Company to provide credit of tax deducted at source to beneficial shareholders in whose hands dividend paid by Company is assessable, shareholders are requested to provide declaration in format as prescribed under Rule 37BA(2) of the Income Tax Rules, 1962.

Section 206AA of the IT Act

Rate of TDS at the rate of 10 percent under Section 194 of the IT Act which is subject to provisions of Section 206AA of the IT Act which introduces special provisions for TDS where PAN provided by deductee is Invalid. Invalid PAN also includes cases where PAN and Aadhar are not linked.

As provided in Section 206AA of the IT Act, tax is required to be deducted at higher of following rates in case of payments to specified person:

- at twice the rate specified in the relevant provisions of the IT Act; or
- at twice the rate or rates in force; or
- at the rate of 20%.

Accordingly, provisions of Section 206AA will be applicable in cases where PAN of the shareholder is Invalid. Validity of PAN will be determined using functionality of Income Tax Department as notified for the purpose of determining specified person under Section 206AB of the IT Act.

Section 206AB of the IT Act

Rate of TDS @10% under Section 194 of the IT Act is subject to provisions of Section 206AB of the IT Act (effective from July 1, 2021) which introduces special provisions for TDS in respect of non-filers of income-tax return. As provided in Section 206AB of the IT Act, tax is required to be deducted at higher of following rates in case of payments to specified persons:

- at twice the rate specified in the relevant provision of the IT Act; or
- at twice the rate or rates in force; or
- at the rate of 5%.

Where Sections 206AA and 206AB of the IT Act are applicable i.e. the specified person has not submitted the PAN as well as not filed the tax return, the tax shall be deducted at the higher of the two rates prescribed in these two sections.

As per Central Board of Direct Taxes vide Circular No. 11 of 2021 dated June 21, 2021, for determining TDS rate on Dividend, the Company will be using functionality of the Income-tax department to determine the applicability of Section 206AB of the IT Act. Rate of 20% will be applied for shareholders who are determined as specified person in Income tax department portal.

The non-resident who does not have the permanent establishment is excluded from the scope of a specified person.

For all shareholders

Shareholders are requested to update tax residential status, Permanent Account Number (PAN), registered email address, mobile numbers and other details with their Depository Participants, in case the shares are held in dematerialised form. Shareholders holding shares in physical mode, are requested to furnish details to the Company's RTA.

The aforementioned forms/ annexures for tax exemption can be downloaded from the website of the Company's RTA - *https://www.bigshareonline.com/Resources.aspx.*

The aforementioned documents (duly completed and signed) are required to be submitted to the Company's RTA at DRLtaxexemption@bigshareonline.com. Alternatively, these declaration can be submitted online also at *https://www.bigshareonline.com/dividendTDS.aspx*. The user shall be prompted to select/ share the information to register their request.

All the documents submitted by the shareholders will be verified by the Company and the Company will consider the same while deducting the appropriate taxes if they are in accordance with the provisions of the IT Act.

Shareholders may note that in case the tax on said dividend is deducted at a higher rate in absence of receipt of the aforementioned details/ documents, option is available to the shareholder to file the return of income as per the IT Act, and claim an appropriate refund, if eligible.

All communications/ queries in this respect should be addressed to our RTA, Bigshare Services Private Limited at their e-mail ID: DRLtaxexemption@bigshareonline.com.

Further, shareholders who have not registered/ updated their email address are requested to register/ update the same on *https://www.drreddys.com/investors/investor-services/shareholder-information/* or with their Depository Participant or send their consent at shares@drreddys.com along with their Folio No. / DP ID and Client ID and valid e-mail address for registration/ updation.

Disclaimer: Above communication on TDS only sets out the provisions of law in a summarised manner and does not purport to be a complete analysis or listing of all potential tax consequences. Shareholders should consult their own tax advisors for the tax provisions applicable to their particular circumstances.

19) Members are requested to contact RTA, Bigshare Services Private Limited for encashing the unclaimed dividends standing to the credit of their account. The detailed dividend history and due dates for transfer to IEPF are given in the Additional Shareholders Information section of the Integrated Annual Report and are also available on the website of the Company at *https://www.drreddys.com/investor#shares.*

20) In terms of requirements of Section 124(6) of the Act read with Investor Education and Protection Fund (IEPF) Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, the Company is required to transfer the shares, in respect of which the dividend remains unpaid or unclaimed for a period of seven consecutive years or more, to the IEPF Account established by the Central Government. The details of the unpaid/ unclaimed dividend amounts lying with the Company as on March 31, 2022 are available on the website of the Company at *https://www.drreddys.com/investor#shares* and on the website of MCA/ IEPF. Member(s) whose dividends/ shares are transferred to the IEPF can claim the same from the IEPF Authority by following the refund procedure as detailed on the IEPF website.

21) SEBI vide Circular dated November 3, 2021, read with Circular dated March 16, 2023, as amended, has made it mandatory for the holders of physical securities to furnish PAN, KYC details and details of nomination. In terms of the said Circulars, the folios wherein any of the above document(s)/details are not available on or after October 1, 2023, shall be frozen by the RTA. The security holder(s) whose folio(s) have been frozen shall be eligible to lodge grievance or avail any service request from the RTA only after furnishing the complete documents/ details, as above. Further, any payment including dividend, interest or redemption payment in respect of such frozen folios, shall be only through electronic mode with effect from April 1, 2024.

As per the said Circulars, the frozen folios are required to be referred by the RTA/ Company to the administering authority under the Benami Transactions (Prohibitions) Act, 1988 and/or Prevention of Money Laundering Act, 2002, if they continue to remain frozen as on December 31, 2025.

Further, the physical shareholders are requested to ensure that their PAN is linked to Aadhaar, if not already done, to avoid freezing of folio.

22) Regulation 40 of the SEBI Listing Regulations, as amended, mandates that transfer of securities shall not be processed unless the securities are held in the dematerialised form with a depository. Further, transmission and transposition of securities held in physical form shall be effected only in dematerialised form. SEBI, vide its Circular dated January 25, 2022, has provided that listed companies, shall issue the securities only in demat mode while processing investor service requests pertaining to issuance of duplicate shares, exchange of shares, endorsement, sub-division/ consolidation of share certificates, transmission, transposition, etc. In view of the above, as also to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to demat mode.

23) Members are hereby informed that for addressing the unresolved disputes pertaining to or emanating from investor services between listed company / RTAs offering services on behalf of the listed company and its shareholders, SEBI vide circular dated May 30, 2022 read with Circular dated April 8, 2022, introduced Standard Operating Procedure to be followed under the Stock Exchange arbitration process.

The mechanism can be initiated only post exhausting all actions for resolution of complaints including those received through the SCORES portal.

24) The Company is pleased to provide the facility of live webcast of proceedings of its 39th AGM. Members who are entitled to participate in the 39th AGM can view the live proceedings of 39th AGM by logging on the NSDL e-voting system at *https://www.evoting.nsdl.com/* using their secure login credentials. Members are encouraged to use this facility of the live webcast. The webcast facility will be available from 9.30 a.m. (IST) onwards (30 minutes before the start of the 39th AGM on July 27, 2023.

25) Since the 39th AGM will be held through VC/ OAVM pursuant to the Circulars, the proxy form, attendance slip and route map have not been annexed to this Notice.

By order of the Board of Directors
For **Dr. Reddy's Laboratories Limited**

Sd/-
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Membership No.F6621

Place: Hyderabad
Date: May 10, 2023

Registered Office
8-2-337, Road No. 3, Banjara Hills,
Hyderabad, Telangana- 500034, India
CIN: L85195TG1984PLC004507
Tel: 91-40-49002900, Fax: 91-40-49002999
Email: shares@drreddys.com
Website: *www.drreddys.com*

EXPLANATORY STATEMENT TO THE NOTICE OF 39TH AGM

Statement pursuant to Section 102 of the Companies Act, 2013, read with the rules made thereunder, as applicable, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Secretarial Standards on General Meetings (SS-2)

ITEM NO. 3

Mr. G V Prasad (DIN: 00057433) is a member of the Company's Board since 1986 and presently designated as the Co-Chairman and Managing Director of the Company. Mr. Prasad is part of promoter group of the Company. Prior to May 2014, Mr. Prasad held titles of Chairman and Chief Executive Officer of the Company.

Mr. G V Prasad was re-appointed as Co-Chairman and Managing Director of the Company at the 36th Annual General Meeting ('AGM') held on July 30, 2020, for a period of five years commencing from January 30, 2021, to January 29, 2026, liable to retire by rotation. He retires by rotation at the 39th AGM of the Company and, being eligible, offers himself for the reappointment.

Mr. Prasad's emphasis on research, innovation, transparency, business ethics and leaner corporate structures has helped to shape Dr. Reddy's into an organisation of global repute, recognised industry-wide for scientific innovation, progressive people practices and high standards of corporate governance. He is driving the necessary imperatives for Dr. Reddy's to engage even more deeply with the human aspects of health. Mr. Prasad also ensures that the Company is well-positioned for the future, drawing upon his 39 years plus of leadership experience in the pharmaceutical industry to help the Company anticipate trends and envision the future of healthcare.

Mr. Prasad as Co-Chairman and Managing Director focuses on mentoring leaders, driving innovation in science, technology and digitalisation while championing the cause of the planet, purpose and patients. He leads the core team that drives the growth and performance at Dr. Reddy's. He has played a key role in the evolution of Dr. Reddy's from a mid-sized pharmaceutical Company into a globally respected pharmaceutical major especially in developed markets. He is also passionate about sustainable manufacturing and business practices. He is widely credited as the architect of Dr. Reddy's successful Global Generics (GG) and Active Pharmaceutical Ingredients (API) strategies, as well as the Company's foray into biosimilars, proprietary products, differentiated formulations and the Company's sustainability initiatives including the adoption of green technologies and processes.

As an advocate of sustainability, Mr. Prasad brought in many initiatives in the Company to enhance the integration of sustainability into the business. His passion for sustainability has helped the organization to take up challenging refreshed ESG goals in 2022. He is a photography enthusiast and supports nature and wildlife. He is involved with the activities of the World Wildlife Fund, Andhra Pradesh and Telangana chapter, Wildlife Trust of India and other conservation-oriented organisations.

Awards and Recognitions: • Named as one of the top 20 leaders on The Medicine Maker's Power List of 2020 & 2021, • Nominated for the YPO Global Impact Awards, 2020, • V. Krishnamurthy Award for Excellence by the Centre for Organisational Development, 2019, • Boundary Breaker leader Award, CEO Awards 2018, • Listed among the Top 50 CEOs that India ever had, Outlook magazine, 2017, • One of the top 5 most valuable CEOs of India by Business World, 2016, • India Business Leader of the year by CNBC Asia, 2015, • India's Best CEO by Business Today, 2014, • India Business Leader of the Year by CNBC Asia, 2014, • India Talent Management Award by CNBC Asia, 2014.

The Company has received declaration in form DIR-8 pursuant to Rule 14 of the Companies (Appointment and Qualification of Directors) Rules, 2014, from Mr. Prasad to the effect that he is not disqualified under Section 164 of the Companies Act, 2013 ('Act') and a declaration that he is not debarred or restrained from acting as a director by any SEBI order or by any other such authority.

Other details of Mr. Prasad pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') and Secretarial Standard - 2 are given in Annexure-A, annexed herewith.

In terms of Section 152 of the Act, the term of office of Mr. Prasad, is subject to retirement by rotation at the ensuing 39th AGM, and being eligible, he seeks re-appointment. The performance evaluation of Mr. Prasad, for the financial year ended March 31, 2023, was carried out by an independent external agency, EgonZehnder, a leadership advisory firm on Board matters, Mr. Prasad was rated highly on the various evaluation parameters carried out by the said agency. The evaluation outcome was placed before the Nomination, Governance and Compensation Committee ('NGCC') and the Board. The Board has discussed the same and expressed profound sense of satisfaction over the evaluation outcome, and while recommending Mr. Prasad's re-appointment for approval of the shareholders, highly appreciated the contribution made by him over the years for the growth and development of the Company.

Except Mr. G V Prasad, Mr. K Satish Reddy, Chairman of the Company and their relatives, none of the other Directors or Key Managerial Personnel of the Company and their relatives are concerned or interested, financially or otherwise, in the resolution set out at item no. 3 of the Notice of the 39th AGM.

The Board, recommends the resolution set forth in item no. 3 of the Notice for approval of the members.

ITEM NO. 4

Pursuant to Section 161 of the Companies Act, 2013 ('Act'), the Board at its meeting held on May 10, 2023, appointed Dr. Claudio Albrecht (DIN: 10109819) as an Additional Director in the category of Independent Director of the Company for a term of five (5) consecutive years with effect from May 10, 2023 to May 9, 2028 (both days inclusive) subject to approval of the shareholders of the Company at the ensuing 39th Annual General Meeting ('AGM') through special resolution.

The Nomination, Governance and Compensation Committee ('NGCC') of the Board periodically discusses the succession of Independent Directors coming up for re-appointment or approaching end of their term. It also assesses the balance of skills, knowledge and experience available with the Board as a whole, in order to maintain orderly succession of the Board. The NGCC had earlier identified the desired attributes for the selection of the Independent Director(s). Basis those attributes, the NGCC has recommended the candidature of Dr. Claudio Albrecht, as an Independent Director of the Company. In the opinion of the Board, Dr. Claudio fulfils the conditions for independence specified in the Act, the Rules made thereunder and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') and other laws / regulations for the time being in force, to the extent applicable to the Company. The Board noted that Dr. Claudio's skills, background and experience are aligned to the attributes identified by the NGCC and that he is eligible for appointment as an Independent Director. The Board was cognizant of following skills and experience of Dr. Claudio, which fit into the criteria of Company's skill matrix in the areas of strategy, finance, governance, management, sustainability, science, technology and operations, which would be beneficial for the Company:

- Experience in leading global pharma companies
- Rich experience in science and technology area
- Knowledge and expertise in strategy design and implementation
- Mergers and Acquisitions
- Rich experience in finance, management and governance
- Organisational design and implementation

The Company has received, *inter alia,* (i) requisite consent from Dr. Claudio to act as an Independent Director, (ii) declaration to the effect that he is not disqualified in accordance with Section 164 of the Act, (iii) declaration that he meets the criteria of independence as provided in Section 149 of the Act and in the SEBI Listing Regulations and (iv) a declaration that he is not debarred or restrained from acting as a Director by any SEBI order or any other such authority. The Company has also received a notice in writing from a member under Section 160 of the Act proposing the candidature of Dr. Claudio as a Director of the Company.

Pursuant to Regulation 17(1C) of the SEBI Listing Regulations, approval of shareholders for appointment of a person on the Board of Directors is required to be taken at the next general meeting or within a time period of three months from the date of appointment, whichever is earlier. Further in terms of Regulation 25(2A) of the SEBI Listing Regulations, the appointment, re-appointment or removal of an Independent Director shall be subject to the approval of shareholders by way of a special resolution. Accordingly, the appointment of Dr. Claudio requires the approval of the members by way of a special resolution.

Hence, in view of the aforementioned provisions, the Company is seeking the approval of its members for appointment of Dr. Claudio, as an Independent Director on the Board of the Company for a term of five consecutive years effective from May 10, 2023 to May 9, 2028.

Profile of Dr. Claudio Albrecht: Dr. Claudio Albrecht, Co-Founder and Managing Partner of Albrecht, Prock & Partners (AP&P) was until August 31, 2018, CEO of the publicly listed STADA AG. Before this assignment Dr. Claudio worked in and with the Generic industry for more than 30 years.

He started his pharmaceutical career at Sandoz in 1987 in Austria and became General Manager of its generic businesses in the Netherlands, in Germany and the USA, before leaving to become CEO of the Ratiopharm Group in 2000. In his time as CEO of the Ratiopharm Group he was driving the internationalisation process of the German drug maker beyond Europe and was material for the initiation of the development, manufacturing and commercialisation project of Ratiopharm's Biosimilars program. Ratiopharm was first to market with the Biosimilar Filgrastim in Europe.

In 2007, Dr. Claudio founded together with Peter Prock the strategy consulting firm CoMeth in Slovakia before he was asked to assume the role of CEO and Chairman of the Board of the Actavis Group. Actavis was operating in over 50 countries worldwide with standalone 2012 revenues in excess of € 2 billion. Under his leadership, Actavis was sold to Watson for USD 6 billion, which represented an above average industry multiple. As CEO of Actavis, Dr. Claudio initiated a total turnaround process and started a joint venture for the development and commercialisation of recombinant Insulin and its analogues with the objective to build the first Generic "one stop shop" in Diabetes.

After the divestiture of Actavis, Dr. Claudio founded with Peter Prock the Zug/Switzerland based Albrecht, Prock & Partners AG. Together with private equity and strategic investors, AP&P worked on numerous acquisition projects amongst which the initiative for STADA AG was the most significant. STADA AG was the largest leveraged buyout of a German listed company ever. Dr. Claudio agreed to manage the company for an interim period of one year and led all the necessary changes and strategic initiatives. In September 2018 Dr. Claudio returned to AP&P.

A copy of the draft letter of appointment, setting out the terms and conditions of appointment of Dr. Claudio, and all other documents referred to in the accompanying Notice and this Statement are available for inspection by the members, at the Company's registered office during business hours on all working days upto the date of 39th AGM.

Other details of Dr. Claudio pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard - 2 are given in Annexure-A, annexed herewith.

In compliance with the provisions of Section 149 read with Schedule IV to the Act and Regulations 17(1C) and 25(2A) of the SEBI Listing Regulations, the approval of the Members is sought for the appointment of Dr. Claudio Albrecht as an Independent Director of the Company, as a special resolution as set out above.

Except Dr. Claudio and his relatives, none of the other Directors or Key Managerial Personnel of the Company and their relatives are concerned or interested, financially or otherwise, in the resolution set out in item no. 4 of the Notice of the 39th AGM.

The Board, recommends the special resolution set forth in item no. 4 of the Notice for approval of the members.

ITEM NO. 5

In terms of Section 149 and other applicable provisions of the Companies Act, 2013 ('Act'), and rules made thereunder, Mr. Leo Puri (DIN: 01764813) was appointed as an Independent Director of the Company for a period of five years with effect from October 25, 2018, to October 24, 2023, by the members at the 35th Annual General Meeting ('AGM') of the Company held on July 30, 2019. Accordingly, he is due for his retirement from the first term as a Non-Executive Independent Director on October 24, 2023.

Section 149(10) of the Act, provides that an Independent Director shall hold office for a term up to five consecutive years on the Board of a Company and shall be eligible for re-appointment, for another term of up to five years, on passing of a special resolution by the members of the Company.

In terms of Section 149 read with Section 152 and Schedule IV of the Act, Mr. Leo Puri is entitled for second term as an Independent Director of the Company. The performance evaluation of Mr. Leo, for the financial year ended March 31, 2023, was carried out by an independent external agency, EgonZehnder, a leadership advisory firm on Board matters, Mr. Leo was rated highly as an Independent Director of the Company on the various evaluation parameters carried out by the said agency. The evaluation outcome was placed before the Nomination, Governance and Compensation Committee ('NGCC') and the Board, and the Board has discussed the same and expressed satisfaction over the evaluation outcome. Consequently, the Board based on the outcome of his performance evaluation and recommendation of the NGCC, is of the opinion that Mr. Leo fulfils the conditions for his re-appointment as an Independent Director as specified in the Act and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), and is independent of the management. The NGCC and the Board are of the view that the continued association of Mr. Leo and his rich experience and vast knowledge that he brings with him, would be beneficial to the Company. The Board also believes that he possesses appropriate skills, expertise and competencies in the context of the Company's businesses, particularly in the areas of strategy, management, governance, human resource, risk and finance.

Considering the above, the NGCC and the Board have recommended to re-appoint Mr. Leo as an Independent Director of the Company, for the second term of five (5) consecutive years from October 25, 2023, to October 24, 2028, not liable to retire by rotation, by passing the special resolution as set out in the Notice of the 39th AGM.

The Company has received, *inter alia*, (i) declaration in form DIR-8 pursuant to Rule 14 of the Companies (Appointment and Qualification of Directors) Rules, 2014, from Mr. Leo to the effect that he is not disqualified under Section 164 of the Act; (ii) declaration that he meets the criteria of independence as provided in the Act and the SEBI Listing Regulations; (iii) declaration that he is not debarred or restrained from acting as a director by any SEBI order or by any other such authority; and (iv) a notice in writing from a member under Section 160 of the Act proposing the candidature of Mr. Leo as an Independent Director of the Company.

Other details of Mr. Leo pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard - 2 are given in Annexure-A, annexed herewith.

Profile of Mr. Leo Puri: Mr. Leo Puri was the Managing Director of UTI Asset Management Co. Limited from August 2013 to August 2018. In his career of more than 30 years, Mr. Leo has previously worked as director with McKinsey & Company and as Managing Director with Warburg Pincus. Mr. Leo has worked in the UK, USA and Asia. Since 1994, he has primarily worked in India. At McKinsey, he has advised leading financial institutions, conglomerates and investment institutions in strategy and operational issues. He has contributed to the development of knowledge and public policy through advice to regulators and government officials. At Warburg Pincus, he was responsible for leading and managing investments across industries in India. He also contributed to financial services investments in the international portfolio as a member of the global partnership.

A copy of the draft letter of re-appointment, setting out the terms and conditions of re-appointment of Mr. Leo, is available for inspection, without any fee, by the members at the Company's registered office during business hours on all working days up to the date of the 39th AGM.

Except Mr. Leo Puri and his relatives, none of the other Directors or Key Managerial Personnel of the Company and their relatives are concerned or interested, financially or otherwise, in the resolution set out in item no. 5 of the Notice of the 39th AGM.

The Board, recommends the special resolution set forth in item no. 5 of the Notice for approval of the members.

ITEM NO. 6

In terms of Section 149 and other applicable provisions of the Companies Act, 2013 ("Act") and rules made thereunder, Ms. Shikha Sharma (DIN: 00043265) was appointed as an Independent Director of the Company for a period of five years with effect from January 31, 2019, to January 30, 2024, by the members at the 35th Annual General Meeting ('AGM') of the Company held on July 30, 2019. Accordingly, she is due for her retirement from the first term as a Non-Executive Independent Director on January 30, 2024.

Section 149(10) of the Act, provides that an Independent Director shall hold office for a term up to five consecutive years on the Board of a Company but shall be eligible for re-appointment, for another term of up to five years, on passing of a special resolution by the shareholders.

In terms of Section 149 read with Section 152 and Schedule IV of the Act, Ms. Shikha Sharma is entitled for second term as an Independent Director of the Company. The performance evaluation of Ms. Shikha, for the financial year ended March 31, 2023, was carried out by an independent external agency, EgonZehnder, a leadership advisory firm on Board matters, Ms. Shikha was rated highly as an Independent Director of the Company on the various evaluation parameters carried out by the said agency. The evaluation outcome was placed before the Nomination, Governance and Compensation Committee ('NGCC') and the Board, and the Board has discussed the same and expressed satisfaction over the evaluation outcome. Consequently, the Board based on the outcome of her performance evaluation and recommendation of the NGCC, is of the opinion that Ms. Shikha Sharma fulfils the conditions for her re-appointment as an Independent Director as specified in the Act and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') and is independent of the management. The NGCC and the Board are of the view that the continued association of Ms. Shikha and her rich experience and vast knowledge that she brings with her would be in the interest of the Company. The Board also believes that she possesses appropriate skills, expertise and competencies in the context of the Company's businesses, particularly in the areas of strategy, management, governance, risk, human resource and finance.

Considering the above, it is recommended to re-appoint Ms. Shikha Sharma as an Independent Director for the second term of five (5) consecutive years from January 31, 2024, up to January 30, 2029, not liable to retire by rotation, by passing the special resolution as set out in the Notice of the 39th AGM.

The Company has received, *inter alia*, (i) declaration in form DIR-8 pursuant to Rule 14 of the Companies (Appointment and Qualification of Directors) Rules, 2014, from Ms. Shikha to the effect that she is not disqualified under Section 164 of the Act; (ii) declaration that she meets the criteria of independence as provided in the Act and the SEBI Listing Regulations; (iii) declaration that she is not debarred or restrained from acting as a Director by any SEBI order or by any other such authority; and (iv) a notice in writing from a member under Section 160 of the Act proposing the candidature of Ms. Shikha as an Independent Director of the Company.

Other details of Ms. Shikha pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard - 2 are given in Annexure-A, annexed herewith.

Profile of Ms. Shikha Sharma: Ms. Shikha Sharma was the Managing Director & CEO of Axis Bank, India's third largest private sector bank from June 2009 upto December 2018. As a leader adept at managing change, she led the Bank on a transformation journey from being primarily a corporate lender to a bank with a strong retail deposit franchise and a balanced lending book.

Ms. Shikha has more than three decades of experience in the financial sector, having begun her career with ICICI Bank Limited in 1980. During her tenure with the ICICI Group, she was instrumental in setting up ICICI Securities. As Managing Director & CEO of ICICI Prudential Life Insurance Company Limited, she led the company to become the No. 1 private sector life insurance company in India. She was a member of RBI's Technical Advisory Committee, Panel on Financial Inclusion, Committee on Comprehensive Financial Services for Small Businesses and Low-Income Household etc. She has chaired CII's National Committee on Banking from 2015 to 2017.

A copy of the draft letter of re-appointment, setting out the terms and conditions of re-appointment of Ms. Shikha, is available for inspection, without any fee, by the members at the Company's registered office during business hours on all working days up to the date of the 39th AGM.

Except Ms. Shikha Sharma and her relatives, none of the other Directors or Key Managerial Personnel of the Company and their relatives are concerned or interested, financially or otherwise, in the resolution set out in item no. 6 of the Notice of the 39th AGM.

The Board, recommends the special resolution set forth in item no. 6 of the Notice for approval of the members.

ITEM NO. 7

The Board of Directors, at its meeting held on May 10, 2023, on the recommendation of the Audit Committee, has approved the re-appointment of M/s. Sagar & Associates, Cost Accountants (Firm Registration No. 000118), as the Cost Auditors of the Company, to conduct the audit of the cost records of the Company for the financial year ending March 31, 2024, at a remuneration of ₹9,00,000/- (Rupees Nine Lakhs only) plus applicable taxes and out of pocket expenses, at actuals in connection with the aforesaid audit. The remuneration for financial year ended March 31, 2022, was ₹7,00,000/- (Rupees Seven Lakh only).

The Board approved the proposed remuneration of the Cost Auditors after considering the scope of the audit involved and cost audit teams requiring fewer members due to the advancement in technology/ software, auditing systems and other automation tools. Therefore, the remuneration of the Cost Auditors being proposed for ratification of the members is commensurate with the scope of work involved.

In terms with the provisions of the Section 148(3) of the Companies Act 2013, read with the Companies (Audit and Auditors) Rules, 2014, members of the Company are required to ratify the remuneration proposed to be paid to the Cost Auditors.

Accordingly, consent of the members is sought for passing an ordinary resolution as set out at item no.7 of the Notice of the 39th Annual General Meeting ("AGM") for ratification of the remuneration payable to the Cost Auditors, for the financial year ending March 31, 2024.

None of the Directors, Key Managerial Personnel and their relatives are, in any way, concerned or interested, financially or otherwise, in this resolution.

The Board, recommends the resolution set forth in item no. 7 of the Notice for approval of the members.

By order of the Board of Directors
For **Dr. Reddy's Laboratories Limited**

Sd/-
K Randhir Singh
Company Secretary, Compliance Officer
and Head-CSR
Membership No. F6621

Place: Hyderabad
Date: May 10, 2023

Registered Office
8-2-337, Road No. 3, Banjara Hills,
Hyderabad, Telangana- 500034, India
CIN: L85195TG1984PLC004507
Tel: 91-40-49002900, Fax: 91-40-49002999
Email: shares@drreddys.com
Website: *www.drreddys.com*

Annexure–A

Name of the Director	Mr. G V Prasad	Dr. Claudio Albrecht	Mr. Leo Puri	Ms. Shikha Sharma
DIN	00057433	10109819	01764813	00043265
Age	62 years	63 years	62 years	64 years
Nationality	Indian	Austrian	British	Indian
Qualification	Bachelor's degree in chemical engineering from Illinois Institute of Technology, Chicago in the USA, and an M.S. in Industrial Administration from Purdue University, Indiana in the USA.	Degree in Law (PhD, Dr. jur.) from University of Innsbruck	Master's degree in P.P.E. from Oxford University, UK as well as Master's degree in Law from Cambridge University, UK.	MBA from the Indian Institute of Management, Ahmedabad, India, B.A. (Hons.) in Economics and Post Graduate Diploma in Software Technology from National Centre for Software Technology (NCST), Mumbai, India.
Expertise in specific areas	Mr. G V Prasad has rich and wide experience in the Company's businesses, particularly in the areas of strategy, management, governance, finance, human resources, sustainability, science, technology and operations. Further details are provided above in item no. 3.	Dr. Claudio Albrecht has rich experience/ expertise in leading global pharma companies; in science and technology area; strategy design and implementation; mergers and Acquisitions; in management and governance; organisational design and implementation; and business and Risk Management, marketing, environment and sustainability. Further details are provided above in item no. 4.	Mr. Leo Puri has rich experience in strategy, management, governance human resource, risk and finance. Further details are provided above in item no. 5.	Ms. Shikha Sharma has rich experience in strategy, management, governance human resource, risk and finance. Further details are provided above in item no. 6.
Date of first appointment	April 8, 1986	May 10, 2023	October 25, 2018	January 31, 2019
Number of shares held in the Company	25,43,418 equity shares of the Company are held in the name of Gunupati Venkateswara Prasad HUF (G V Prasad HUF). Further, APS Trust holds 34,345,308 equity shares of the Company, in the name of Mr. G V Prasad jointly with Mr. K Satish Reddy. Mr. G V Prasad, Mr. K Satish Reddy, Mrs. G Anuradha, Mrs. Deepti Reddy and their bloodline descendants are the beneficiaries of APS Trust.	Nil	Nil	Nil
Name of other Companies in which he holds Directorship	**Company's subsidiaries including step-down subsidiaries:** Aurigene Oncology Limited and Idea2Enterprises (India) Private Limited in India; Aurigene Discovery Technologies Inc., Dr. Reddy's Laboratories, Inc., and Promius Pharma LLC in USA **Other Companies:** Greenpark Hotels and Resorts Limited, Stamlo Industries Limited, Dr. Reddy's Trust Services Private Limited, Dr. Reddy's Institute of Life Sciences, International Foundation for Research and Education, Indian School of Business in India. Apart from the Company, he was not a Director in any other listed entities during past three years.	Oripharm Group A/S, MS Pharma, GMS Holdings, Six Rays He was not a director in any listed entity during last three years.	Hindustan Unilever Limited, TATA Sons Private Limited, JP Morgan Services India Private Limited. Listed entities from which Mr. Leo Puri has resigned in the past three years: Nil	TATA Consumer Products Limited, Piramal Enterprises Limited, Tech Mahindra Limited, Mahindra and Mahindra Limited. Listed entities from which Ms. Shikha Sharma has resigned in the past three years: Ambuja Cements Limited (Date of cessation – September 16, 2022)

Name of the Director	Mr. G V Prasad	Dr. Claudio Albrecht	Mr. Leo Puri	Ms. Shikha Sharma
Chairman/ Member of the Committee(s) of Board of Directors	**Dr. Reddy's Laboratories Limited:** Member of the Sustainability and CSR Committee, Stakeholders' Relationship Committee and Banking and Authorisations Committee. **Aurigene Oncology Limited:** Member of the Corporate Social Responsibility Committee.	**Dr. Reddy's Laboratories Limited:** Chairman of the Science, Technology and Operations Committee and Member of the Risk Management Committee.	**Dr. Reddy's Laboratories Limited:** Member of Risk Management Committee and Science, Technology and Operations Committee. **Hindustan Unilever Limited:** Member of the Stakeholders Relationship Committee and Corporate Social Responsibility Committee.	**Dr. Reddy's Laboratories Limited:** Chairperson of Risk Management Committee and Member of Audit Committee. **TATA Consumer Products Limited:** Member of Audit Committee, Nomination and Remuneration Committee, Risk Management Committee and Corporate Social Responsibility Committee. **Piramal Enterprises Limited:** Member of Nomination and Remuneration Committee and Risk Management Committee. **Tech Mahindra Limited:** Member of Nomination and Remuneration Committee and Risk Management Committee. **Mahindra and Mahindra Limited:** Member of Audit Committee, Nomination and Remuneration Committee and Risk Management Committee.
Relationships between Directors inter-se	Mr. G V Prasad is brother-in-law of Mr. K Satish Reddy, Chairman of the Company and is not 'relative' as defined under the Companies Act, 2013. Mr. Prasad is not related to any other Director or Key Managerial Personnel of the Company.	Dr. Claudio Albrecht is not related to any Director or Key Managerial Personnel of the Company.	Mr. Leo Puri is not related to any Director or Key Managerial Personnel of the Company.	Ms. Shikha Sharma is not related to any Director or Key Managerial Personnel of the Company.
Number of Board meetings attended	Attended all 8 Board meetings held during the financial year ended March 31, 2023.	Dr. Claudio appointed as an Independent Director of the Company with effect from May 10, 2023.	Attended all 8 Board meetings held during the financial year ended March 31, 2023.	Attended 7 Board meetings held during the financial year ended March 31, 2023.

Name of the Director	Mr. G V Prasad	Dr. Claudio Albrecht	Mr. Leo Puri	Ms. Shikha Sharma
Terms of appointment along with details of remuneration sought to be paid and the remuneration last drawn by such person, if applicable.	**Term:** Members of the Company at their AGM held on July 30, 2020, has approved the re-appointment and terms of remuneration of Mr. G V Prasad for a period of five years, with effect from January 30, 2021 as Co-Chairman and Managing Director of the Company. His re-appointment is subject to retire by rotation in terms of the provisions of the Act. **Remuneration for the financial year ended March 31, 2023:** Salary- ₹14.4 million Perquisites- ₹13.3 million Commission- ₹160 million For the financial year ended March 31, 2023, Mr. G V Prasad was entitled to receive commission upto ₹294 million, i.e. @0.75 of the profit calculated under Section 198 of the Act, as approved by the members of the Company at their AGM held on July 30, 2020. In line with the approval given by the members of the Company, the NGCC and the Board has approved commission of ₹160 million to Mr. G V Prasad for the financial year ended March 31, 2023. Mr. G V Prasad will be entitled for remuneration for his terms of office in terms of approval given by the members at their AGM held on July 30, 2020, and as approved by the NGCC and the Board of the Company. He is not entitled for any stock option pursuant to Employees Stock Option Schemes of the Company.	**Term:** Appointed as an Independent Director for a term of five consecutive years commencing from May 10, 2023 to May 9, 2028, subject to the approval of Members. **Remuneration for the financial year ended March 31, 2023:** Not applicable **Remuneration sought to be paid:** Dr. Claudio will be entitled for remuneration by way of commission, as payable to other Independent Directors of the Company, as may be decided by the Board of Directors of the Company. He will not be entitled for any stock option pursuant to Employees Stock Option Schemes of the Company. The Members of the Company had earlier approved for payment of remuneration by way of commission to its Directors (whether existing or future) other than the Managing/ Whole-time Directors, collectively up to 1% of the net profits of the Company every year, computed in the manner referred to in Section 198 of the Companies Act, 2013, in such proportion/ manner as may be determined by the Board of Directors of the Company, in addition to the payment of sitting fees and reimbursement of expenses, if any, to the Directors for attending the meetings of the Board of Directors or Committees thereof.	**Term:** Re-appointment as an Independent Director for second term of five consecutive years commencing from October 25, 2023 to October 24, 2028. **Remuneration for the financial year ended March 31, 2023:** ₹15.3 million **Remuneration sought to be paid:** Mr. Leo will be entitled for remuneration by way of commission, as payable to other Independent Directors of the Company, as may be decided by the Board of Directors of the Company. He will not be entitled for any stock option pursuant to Employees Stock Option Schemes of the Company. The Members of the Company had earlier approved for payment of remuneration by way of commission to its Directors (whether existing or future) other than the Managing/ Whole-time Directors, collectively up to 1% of the net profits of the Company every year, computed in the manner referred to in Section 198 of the Companies Act, 2013, in such proportion/ manner as may be determined by the Board of Directors of the Company, in addition to the payment of sitting fees and reimbursement of expenses, if any, to the Directors for attending the meetings of the Board of Directors or Committees thereof.	**Term:** Re-appointment as an Independent Director for second term of five consecutive years commencing from January 31, 2024, up to January 30, 2029. **Remuneration for the financial year ended March 31, 2023:** ₹13.1 million **Remuneration sought to be paid:** Ms. Shikha will be entitled for remuneration by way of commission, as payable to other Independent Directors of the Company, as may be decided by the Board of Directors of the Company. He will not be entitled for any stock option pursuant to Employees Stock Option Schemes of the Company. The Members of the Company had earlier approved for payment of remuneration by way of commission to its Directors (whether existing or future) other than the Managing/ Whole-time Directors, collectively up to 1% of the net profits of the Company every year, computed in the manner referred to in Section 198 of the Companies Act, 2013, in such proportion/ manner as may be determined by the Board of Directors of the Company, in addition to the payment of sitting fees and reimbursement of expenses, if any, to the Directors for attending the meetings of the Board of Directors or Committees thereof.

Dr.Reddy's

INSTRUCTIONS FOR E-VOTING

Pursuant to the provisions of Section 108 of the Companies Act, 2013 ("Act") read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended, Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended, and applicable Circulars, the Company is pleased to provide the facility to Members to exercise their right to vote on the resolutions proposed to be passed at 39th AGM to be held on Thursday, July 27, 2023, at 10.00 a.m. (IST) by electronic means. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL), as the authorised agency for facilitating voting through electronic means. The facility of casting votes by a Member using remote e-voting system as well as e-voting on the date of the AGM will be provided by NSDL.

The remote e-voting facility is available at the link, *www.evoting.nsdl.com.* The e-voting event number (EVEN) and period of remote e-voting are set out below:

Date of 39th AGM	EVEN	Commencement of remote e-voting	End of remote e-voting
Thursday, July 27, 2023, at 10:00 a.m. (IST)	124171	Sunday, July 23, 2023, at 9:00 a.m. (IST)	Wednesday, July 26, 2023, at 5:00 p.m. (IST)

The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members/ Beneficial Owners as on the record date (cut-off date) i.e. Thursday, July 20, 2023, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date.

Please read the instructions printed below before exercising your vote. The details and instructions for e-voting and participation at the AGM through VC/ OAVM form an integral part of this Notice of the 39th AGM.

HOW DO I VOTE ELECTRONICALLY USING NSDL E-VOTING SYSTEM?

The way to vote electronically on NSDL e-voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-voting system

Step 2: Cast your vote electronically and join General Meeting on NSDL e-voting system.

STEP 1: ACCESS TO NSDL E-VOTING SYSTEM

A) Login method for e-voting and joining virtual meeting for Individual shareholders holding securities in demat mode. In terms of SEBI circular dated December 9, 2020 on e-voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. *https://eservices.nsdl.com* either on a Personal Computer or on a mobile. On the e-Services home page click on the **"Beneficial Owner"** icon under **"Login"** which is available under **'IDeAS'** section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-voting services under Value added services. Click on **"Access to e-voting"** under e-voting services and you will be able to see e-voting page. Click on company name or e-voting service provider i.e. NSDL and you will be re-directed to **e-voting website of NSDL** for casting your vote during the remote e-voting period or joining virtual meeting & voting during the meeting. 2. If you are not registered for IDeAS e-Services, option to register is available at *https://eservices.nsdl.com.* Select **"Register Online for IDeAS Portal"** or click at *https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp* 3. Visit the e-voting website of NSDL. Open web browser by typing the following URL: *https://www.evoting.nsdl.com/* either on a Personal Computer or on a mobile. Once the home page of e-voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-voting page. Click on company name or **e-voting service provider i.e. NSDL** and you will be redirected to e-voting website of NSDL for casting your vote during the remote e-voting period or joining virtual meeting & voting during the meeting.

Type of shareholders	Login Method
	4. Shareholders/Members can also download NSDL Mobile App **“NSDL Speede”** facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on Download on the App Store GET IT ON Google Play
Individual Shareholders holding securities in demat mode with CDSL	1. Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-voting page without any further authentication. The URL for users to login to Easi / Easiest are *https://web.cdslindia.com/myeasi/home/login* or *www.cdslindia.com* and click on New System Myeasi. 2. After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of **e-voting service provider i.e. NSDL.** Click on **NSDL** to cast your vote. 3. If the user is not registered for Easi/Easiest, option to register is available at *https://web.cdslindia.com/myeasi/Registration/EasiRegistration* Click on login & New System Myeasi Tab and then click on registration option 4. Alternatively, the user can directly access e-voting page by providing demat Account Number and PAN No. from a link in *www.cdslindia.com* home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. **NSDL** where the e-voting is in progress and also able to directly access the system of all e-voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-voting facility upon logging in, you will be able to see e-voting option. Click on e-voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-voting feature. Click on company name or e-voting service provider i.e. NSDL and you will be redirected to e-voting website of NSDL for casting your vote during the remote e-voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL:

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at +91-22-48867000 and +91-22-24997000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

B) Login Method for e-voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-voting website?

1. Visit the e-voting website of NSDL. Open web browser by typing the following URL: *https://www.evoting.nsdl.com/* either on a Personal Computer or on a mobile.
2. Once the home page of e-voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the Company For example if folio number is 001*** and EVEN is 124171 then user ID is 124171001***

5. Password details for shareholders other than Individual shareholders are given below:
   a) If you are already registered for e-voting, then you can use your existing password to login and cast your vote.
   b) If you are using NSDL e-voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
   c) How to retrieve your 'initial password'?
      (i) If your email ID is registered in your demat account or with the Company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
      (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
   a) Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on *www.evoting.nsdl.com.*
   b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on *www.evoting.nsdl.com.*
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-voting will open.

STEP 2: CAST YOUR VOTE ELECTRONICALLY AND JOIN GENERAL MEETING ON NSDL E-VOTING SYSTEM

How to cast your vote electronically and join General Meeting on NSDL e-voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of Company for which you wish to cast your vote during the remote e-voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join General Meeting".
3. Now you are ready for e-voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

GENERAL GUIDELINES FOR SHAREHOLDERS

1. Any person, who acquires shares of the Company and becomes a Member of the Company after dispatch of the Notice of the 39th AGM and holds shares as on the cut-off date i.e. Thursday, July 20, 2023, may obtain user ID and password by sending a request at evoting@nsdl.co.in. However, if you are already registered with NSDL for e-voting, then you can use your existing User ID and Password for casting your vote.
2. The members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.
3. The facility for voting through electronic voting system shall be made available during the AGM and only those members, who will be present in the AGM through VC/ OAVM facility and have not cast their vote on the resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system in the AGM.
4. The voting rights of members shall be in proportion to the shares held by them, of the paid-up equity share capital of the company as on the cut-off date.
5. Ms. Rashida Adenwala, founding partner of M/s. R & A Associates, Practicing Company Secretary, Hyderabad (Membership No. 4020 & Certificate of Practice No. 2224) has been appointed by the Board as the scrutiniser to scrutinise the voting through electronic means during the 39th AGM and remote e-voting process in a fair and transparent manner.
6. Immediately after the conclusion of voting at the 39th AGM, the scrutiniser shall first count the votes cast at the AGM and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company. The scrutiniser shall prepare a Consolidated Scrutiniser’s Report of the total votes cast in favor or against, if any, not later than forty-eight hours after the conclusion of the 39th AGM. This report shall be made to the Chairman or any other person authorised by the Chairman, who shall declare the result of the voting forthwith.
7. The voting results declared along with the scrutiniser’s report shall be placed on the Company’s website *www.drreddys.com* and the website of NSDL immediately after the declaration of the result by the Chairman or a person authorised by the Chairman. The results shall also be immediately forwarded to the BSE Limited, National Stock Exchange of India Limited, the New York Stock Exchange Inc. and NSE IFSC Limited.
8. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “Forgot User Details/Password?” or “Physical User Reset Password?” option available on *www.evoting.nsdl.com* to reset the password.
9. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of *www.evoting.nsdl.com* or call on Toll Free No.: +91-22-48867000 and +91-22-24997000 or send a request at evoting@nsdl.co.in

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL IDS ARE NOT REGISTERED WITH THE DEPOSITORIES FOR PROCURING USER ID AND PASSWORD AND REGISTRATION OF EMAIL IDS FOR E-VOTING ON THE RESOLUTIONS SET OUT IN THIS NOTICE

1. In case shares are held in physical mode members are requested to provide Folio No., name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to the Company at shares@drreddys.com or to the RTA at bsshyd@bigshareonline.com.
2. In case shares are held in demat mode, members are requested to provide DP ID and Client ID (16 digit DP ID + Client ID or 16 digit beneficiary ID), name, client master or copy of consolidated account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to the Company at shares@drreddys.com or to the RTA at bsshyd@bigshareonline.com. If you are an individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-voting and joining virtual meeting for Individual shareholders holding securities in demat mode.
3. Alternatively, shareholder/members may send a request to evoting@nsdl.co.in for procuring user ID and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020, on e-voting facility provided by listed companies, individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-voting facility.

INSTRUCTIONS FOR MEMBERS FOR E-VOTING ON THE DAY OF THE 39TH AGM

1. The procedure for e-voting on the day of the 39th AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present at the 39th AGM through VC/ OAVM facility and have not casted their vote on the resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system at the 39th AGM.
3. Members who have voted through remote e-voting will be eligible to attend the 39th AGM. However, they will not be eligible to vote at the 39th AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-voting on the day of the 39th AGM shall be the same person mentioned for remote e-voting.

INSTRUCTIONS FOR MEMBERS ATTENDING THE 39TH AGM THROUGH VC/ OAVM

1. Member will be provided with a facility to attend the 39th AGM through VC/ OAVM through the NSDL e-voting system. Members may access by following the steps mentioned above for **Access to NSDL e-voting system**. After successful login, you can see link of "VC/ OAVM" placed under **"Join meeting"** menu against company name. Members are requested to click on VC/ OAVM link placed under Join Meeting menu. The link for VC/ OAVM will be available in Shareholder/ Member login where the EVEN of the Company will be displayed. Members who do not have the User ID and Password for e-voting or have forgotten the User ID and Password may retrieve the same by following the remote e-voting instructions mentioned in the Notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further, Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Participants connecting from mobile devices or tablets or through laptop connecting via mobile hotspot may experience audio/ video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any kind of aforesaid glitches.

5. Members who would like to express their views/ have questions with regard to the financial statements or any other matter to be placed at the 39th AGM may send their questions in advance mentioning their name, demat account number/ Folio number, email id & mobile number at shares@drreddys.com on or before July 23, 2023 (6:00 p.m. IST). The same will be replied by the Company suitably.
6. Those members who have registered themselves as a speaker in advance will only be allowed to express their views/ ask questions during the meeting.
7. The Company reserves the right to limit the number of speakers depending on the availability of time at the 39th AGM.
8. In case any assistance is needed, members may contact:
   a. Mr. Amit Vishal, Senior Manager, NSDL at amitv@nsdl.co.in or at telephone number: +91-22-24994360.
   b. Ms. Pallavi Mhatre, Manager, NSDL at pallavid@nsdl.co.in or at telephone number: +91-22-24994545.
   c. NSDL at evoting@nsdl.co.in or at +91-22-48867000 and +91-22-24997000.

By order of the Board of Directors
For **Dr. Reddy's Laboratories Limited**

Sd/-
K Randhir Singh
Company Secretary, Compliance Officer
and Head-CSR
Membership No. F6621

Place: Hyderabad
Date: May 10, 2023

Registered Office
8-2-337, Road No. 3, Banjara Hills,
Hyderabad, Telangana- 500034, India
CIN: L85195TG1984PLC004507
Tel-91-40-49002900, Fax-91-40-49002999
Email: shares@drreddys.com
Website: *www.drreddys.com*

39TH AGM INFORMATION AT A GLANCE

Time and date of 39th AGM	10.00 a.m. (IST), Thursday, July 27, 2023
Mode	Video conference and other audio-visual means
Helpline number for VC participation	+91-22-4886 7000 and +91-22-2499 7000
Webcast and transcripts	*https://drreddys.com/investor#reports-and-filing#annual-general-meeting*
Cut-off date for e-voting	Thursday, July 20, 2023
E-voting start time and date	9:00 a.m. (IST), Sunday, July 23, 2023
E-voting end time and date	5:00 p.m. (IST), Wednesday, July 26, 2023
E-voting website of NSDL	*https://www.evoting.nsdl.com/*
Name, address and contact details of e-voting service provider	Contact details: National Securities Depository Limited, 4th Floor, A Wing, Trade World, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai 400013, India Contact number: +91-22-48867000 and +91-22-24997000 Contact person: Mr. Amit Vishal, Assistant Vice President *AmitV@nsdl.co.in*; +91-22-24994360 Ms. Pallavi Mhatre, Senior Manager *pallavid@nsdl.co.in*; +91-22-24994545
Name, address and contact details of Registrar and Transfer Agent	Contact details: Bigshare Services Pvt. Ltd 306, Right Wing, 3rd Floor, Amrutha Ville, Opp. Yashoda Hospital, Somajiguda, Rajbhavan Road Hyderabad – 500082, India *bsshyd@bigshareonline.com*; +91-40-23374967 Contact person: Mr. Prabhakar S.D, Deputy General Manager *prabhakar@bigshareonline.com* Mr. Amarendranath.R, Manager amarendranath.r@bigshareonline.com
Name, address and contact details of the Company	Dr. Reddy's Laboratories Limited 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana- 500034, India Tel-91-40-49002900, Fax-91-40-49002999 Email: *shares@drreddys.com;* Website: *www.drreddys.com*
Final dividend record date	Tuesday, July 11, 2023
Dividend payment date	Tuesday, August 1, 2023
Information of tax on final dividend for the financial year ended March 31, 2023	*https://www.drreddys.com/investor#investor-services#statutory-communication*